Endo International plc (OTC: ENDPQ), an American-Irish specialty pharmaceutical company, announced on Wednesday that its subsidiary Endo Ventures Limited has signed a contract with United States-based MAIA Pharmaceuticals, Inc. to distribute bivalirudin injection in a ready-to-use 250mg/50mL single-use vial in the United States.

Endo is to commercialise the FDA-approved product via its Par Sterile Products business and is expected to commence shipping this summer.

Scott Sims, SVP and General Manager, Injectable Solutions & Generics at Endo, said, 'Hospital providers have told us what they need--ready-to-use medications that allow them to focus on patients rather than preparation. Through this partnership with MAIA Pharmaceuticals, we are proud to answer that call with the only ready-to-use liquid format of bivalirudin.'